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Abstract
Introduction Treatment with estrogen and progesterone (E+P)
mimics the protective effect of parity on mammary tumors in
rodents and depends upon the activity of p53. The following
experiments tested whether exogenous E+P primes p53 to be
more responsive to DNA damage and whether these pathways
confer resistance to mammary tumors in a mouse model of Li-
Fraumeni syndrome.
Methods Mice that differ in p53 status (Trp53+/+,  Trp53+/-,
Trp53-/-) were treated with E+P for 14 days and then were
tested for p53-dependent responses to ionizing radiation.
Responses were also examined in parous and age-matched
virgins. The effects of hormonal exposures on tumor incidence
were examined in BALB/c-Trp53+/- mammary tissues.
Results Nuclear accumulation of p53 and apoptotic responses
were increased similarly in the mammary epithelium from E+P-
treated and parous mice compared with placebo and age-
matched virgins. This effect was sustained for at least 7 weeks
after E+P treatment and did not depend on the continued
presence of ovarian hormones. Hormone stimulation also
enhanced apoptotic responses to ionizing radiation in BALB/c-
Trp53+/- mice but these responses were intermediate compared
with Trp53+/+ and Trp-/- tissues, indicating haploinsufficiency.
The appearance of spontaneous mammary tumors was delayed
by parity in BALB/c-Trp53+/- mice. The majority of tumors lacked
estrogen receptor (ER), but ER+ tumors were observed in both
nulliparous and parous mice. However, apoptotic responses to
ionizing radiation and tumor incidence did not differ among
outgrowths of epithelial transplants from E+P-treated donors
and nulliparous donors.
Conclusion Therefore, E+P and parity confer a sustained
increase in p53-mediated apoptosis within the mammary
epithelium and suppress mammary tumorigenesis, but this
effect was not retained in epithelial outgrowths.
Introduction
Breast cancer is the most frequent type of cancer among
women in the US and ranks as the second leading cause of
cancer death [1]. Reproductive history predicts the potential
for breast cancer development. For instance, early menarche
or late menopause increases lifetime exposure to estrogen
and both are associated with increased breast cancer risk
[2,3]. However, a full-term pregnancy early in reproductive life
reduces breast cancer incidence in women by up to 50%
[4,5]. Pregnancy also reduces the incidence of carcinogen-
induced mammary tumors in rodents [6]. Treatment with estro-
gen and progesterone (E+P) to mimic serum levels during
pregnancy is sufficient to reduce the incidence of carcinogen-
induced mammary tumors in rodents [7-9].
Although E+P can render the mammary epithelium resistant to
tumors, the underlying mechanisms mediating the protective
AMV = age-matched virgin; E+P = estradiol and progesterone; ER = estrogen receptor; DMEM = Dulbecco's modified Eagle's medium; MIN = mam-
mary intra-epithelial neoplasias; Trp53 = transformation-related protein 53 (gene in mouse encoding the p53 tumor suppressor protein); TUNEL = 
terminal uridine deoxynucleotidyl transferase dUTP nick-end labeling.Breast Cancer Research    Vol 10 No 3    Dunphy et al.
Page 2 of 15
(page number not for citation purposes)
effect of parity are unknown. It has been proposed that the
bolus of ovarian hormones during pregnancy initiates persist-
ent systemic changes in the parous individual. Reductions in
growth hormone and prolactin have been associated with
decreased breast cancer risk [10-12]. Serum estrogen is also
decreased in parous rodents [13]. These changes in the
hypothalamic-hypophysial axis would limit the proliferative
stimulus to preneoplastic cells and, therefore, reduce the pro-
motional environment for cancer.
Parity also induces changes within the mammary gland, which
may prevent tumors. Pregnancy causes morphological
changes, including differentiation of the epithelial tree in prep-
aration for lactation, which could alter tumor susceptibility
[14]. However, differentiation alone is not sufficient, because
prolactin stimulates morphological differentiation but does not
render the mammary gland refractory to carcinogen-induced
tumors [15]. In addition to morphological differentiation, preg-
nancy causes permanent changes in the epithelial cells and
stroma of the mammary gland [16-18]. Differential expression
of growth-regulatory genes such as amphiregulin, pleiotrophin,
insulin-like growth factor-1, and transforming growth factor-
beta-3 has been reported in parous mammary tissue [19,20]
and may limit carcinogenesis in the mammary epithelium.
While alteration in these growth factor signaling pathways may
mediate signals from E+P receptors, the p53 pathway
appears to be a crucial downstream effector. Both p53 and its
downstream transcriptional target, Cdkn1a  (also known as
p21/WAF1), are increased in parous and E+P-treated mam-
mary epithelium in response to 7,12-diamethylbenz [a]anthra-
cene [21]. In the absence of p53, the protection afforded by
parity or exogenous E+P is lost [22,23]. Exposure to ionizing
radiation causes DNA double-strand breaks and is a risk factor
for breast cancer in women [24,25]. Furthermore, p53-
dependent responses to ionizing radiation are modest in mam-
mary epithelium of nulliparous mice [26] but are enhanced dur-
ing pregnancy and by treatment with E+P for 3 days [27].
Breast cancer is the most common tumor among women with
Li-Fraumeni syndrome, a syndrome associated with hetero-
zygous mutations in the gene encoding p53 protein [28,29],
highlighting the important role of p53 in susceptibility to breast
cancer. Whether the susceptibility to breast cancer in Li-Frau-
meni syndrome is due to increased risk of loss of heterozygos-
ity for TP53 or due to diminished p53 activity is unclear.
In these experiments, we demonstrate that p53-dependent
apoptosis is increased by both parity and E+P treatment and
that p53 sensitivity is retained after withdrawal of systemic
hormones. Hormone-stimulated p53-dependent apoptosis
and hormone-induced protection were evident even when p53
activity was reduced because of haploinsufficiency in BALB/
c-Trp53+/- mice. Consistent with the increased responsive-
ness of p53, the latency of spontaneous mammary tumors in
BALB/c-Trp53+/- mice was increased among parous mice
compared with nulliparous mice. However, neither enhanced
p53 responsiveness nor suppression of tumors was retained
in outgrowths from hormone-stimulated BALB/c-Trp53+/-
mammary epithelium when transplanted into nulliparous hosts.
Materials and methods
Animal treatments
BALB/c mice used in these experiments were housed in tem-
perature-controlled facilities with a 12-hour alternating day/
night light cycle. All mice were of BALB/cMed genetic back-
ground and include Trp53+/+, Trp53+/-, and Trp53-/-. All mice
were maintained on AIN76A (Harlan Teklad, Madison, WI,
USA) soy-free diet and water ad libitum. Six hours prior to sac-
rifice, animals received either a 5-Gy dose of γ-irradiation from
a cesium-137 source (radiation response) or no γ-irradiation
(spontaneous response). At sacrifice, the stage of estrus was
determined by vaginal smear. The fourth mammary glands
were harvested, fixed overnight in 10% neutral-buffered forma-
lin, and embedded in paraffin. All animals were maintained in
accordance with procedures approved by the Institutional Ani-
mal Care and Use Committee (project #25-09-19). The treat-
ment groups for animals are summarized below.
Neonatal E+P or placebo
At 10 days of age, a single 14-day release pellet containing
E+P (0.05 mg 17β-estradiol and 3 mg progesterone) or pla-
cebo (Innovative Research of America, Sarasota, FL, USA)
was implanted subcutaneously as outlined in Figure 3a. Mice
were returned to their dams and allowed to mature normally.
The fourth mammary glands were harvested at 10 weeks of
age.
Mature E+P or placebo
At 6 weeks of age, a single 14-day release pellet containing
E+P (0.05 mg estradiol and 3 mg progesterone) or placebo
(Innovative Research of America) was implanted subcutane-
ously as outlined in Figure 3a. The fourth mammary glands
were harvested at 10 weeks of age.
Parous and age-matched virgin
At 5 weeks of age, female mice were mated to produce parous
females. After parturition, females were permitted to nurse for
7 days and then were force-weaned and allowed to involute for
28 days. At the time of tissue harvest, parous mice were usu-
ally between 14 and 15 weeks of age. Age-matched virgin
(AMV) mice controls were also collected between 14 and 15
weeks of age. The timeline for treatment of mice is outlined in
Figure 3a.
Ovariectomized E+P and nulliparous mice
BALB/c-Trp53+/+ mice were hormone-treated as per mature
E+P and placebo-treated mice. At approximately 11 weeks of
age, mice were ovariectomized. Endogenous ovarian hor-
mones were allowed to clear for 2 weeks. At approximately 13
weeks of age, all mice received a 5-Gy dose of γ-irradiation 6Available online http://breast-cancer-research.com/content/10/3/R43
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hours prior to harvest of the fourth mammary glands. The time-
line for the treatments is shown in Figure 4a.
Whole organ culture
BALB/c-Trp53+/+ mice were hormone-treated as per mature
E+P or placebo. At 12 weeks of age, the fourth inguinal mam-
mary gland was harvested under aseptic conditions, divided
into two portions, and floated on Ferrosan surgifoam sponge
(Ethicon Inc., Somerville, NJ, USA) in 2 mL of serum-free phe-
nol-red-free Dulbecco's modified Eagle's medium (DMEM)/F-
12 (1:1) media supplemented with insulin as described previ-
ously [26,27]. The timeline for treatment of mice and tissues is
shown in Figure 5a.
Spontaneous tumor study
A total of 44 nulliparous and 52 parous BALB/c-Trp53+/- mice
bred in our facility were monitored for up to 74 weeks for the
appearance of tumors. Mammary tumor latency was recorded
as the week of first detection by palpation.
Epithelial transplant study
Donor mammary epithelium was obtained from the fourth
mammary glands of 12- to 15-week-old BALB/c-Trp53+/-
female mice that were treated as described above: they were
treated neonatally with either E+P or placebo and were parous
or AMVs. The timelines for treatment of donor mice are sum-
marized in Figure 8a. The tissues were minced, then placed in
cryovials containing 1 mL of DMEM/F-12 supplemented with
10% fetal bovine serum and 10% dimethylsulfoxide, and
stored in liquid nitrogen until needed for transplantation.
Fragments (~1 mm3) of hormone-stimulated epithelium (E+P
or parous) and nulliparous epithelium (placebo or AMV) were
transplanted into contralateral mammary fat pads cleared of
endogenous epithelium of the same host mouse as described
previously [22]. The transplant epithelium was allowed to fill
the fat pad. At 10 weeks of age, one group of mice bearing
transplants was subjected to 5 Gy of γ-irradiation 6 hours prior
to tissue harvest for TUNEL (terminal uridine deoxynucleotidyl
transferase dUTP nick-end labeling) assay (see timeline in Fig-
ure 8b). Another group was subjected to four weekly doses of
1.2 Gy of γ-irradiation [30] and used for the tumor study (see
timeline in Figure 9). Animals in the tumor study were moni-
tored by mammary gland palpation for up to 65 weeks. Tumors
were removed when less than 1 cm in diameter to allow the
continued monitoring of the contralateral gland. At the end of
the tumor study, whole mounts were prepared for all remaining




Four-micrometer paraffin-embedded sections were deparaffin-
ized and subjected to TUNEL using a TdT-FragEL DNA Frag-
mentation Detection Kit (Calbiochem, now part of EMD
Biosciences, Inc., San Diego, CA, USA). Tissues were
counterstained with methyl green and analyzed for apoptosis
by counting 1,200 cells per slide, with the exception of the
whole organ culture, where 600 cells per slide were counted.
Immunohistochemistry
Immunohistochemistry was performed on a Dako autostainer
(Dako, Carpinteria, CA, USA). After antigen-retrieval and
blocking steps, 4-μm sections were incubated with primary
antibodies recognizing p53 (CM5; Novacastra, now part of
Leica Microsystems, Wetzlar, Germany) (diluted 1:200) or
estrogen receptor (ER)-α (MC 20; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) (diluted 1:200). The signal was ampli-
fied using a biotinylated polymer (Vector Laboratories, Burlin-
game, CA, USA) and detected with diaminobenzidine. Tissues
were counterstained with hematoxylin.
Histopathology
Tumor tissues were fixed overnight in neutral-buffered forma-
lin, processed, and stained with hematoxylin and eosin for his-
tological assessment. The histological evaluations were
conducted using the criteria described for genetically engi-
neered mice [31]. Tissues were considered positive for ERα
nuclear staining similar to or exceeding the intensity observed
in normal ducts.
Whole mount preparation
Whole mammary glands were fixed in Carnoy's fixative (6:3:1
ethanol/chloroform/glacial acetic acid) and then stained in car-
mine alum solution (2 g/L carmine; 10 mM aluminum potas-
sium). Glands were dehydrated in graded ethanol, cleared in
xylenes, and mounted on slides with permount.
Microscopy
A Spot digital camera (Diagnostic Instruments, Sterling
Heights, MI, USA) mounted on a Zeiss Axioscope microscope
(Carl Zeiss, Jena, Germany) was used to acquire figures. The
magnification is noted for each image.
Statistical analysis
Quantification of TUNEL and p53
Thresholds for detection were set to determine positive stain-
ing for p53 and TUNEL using BIOQUANT Imaging software
(BIOQUANT Image Analysis Corporation, Nashville, TN,
USA). A total of 1,200 mammary epithelial cells were counted
for each specimen, except for whole organ cultures, where
600 cells per specimen were counted. The two-sided Student
t test was used to determine differences between groups. A P
value of less than 0.05 was considered significantly different.
Error bars indicate the standard error of the mean.
Analysis of variance was used to test the effects of Trp53 gen-
otype and hormone treatments on apoptosis. Survival of
Trp53-deficient mice was limited in some treatments, due to
spontaneous nonmammary tumors that are common in theseBreast Cancer Research    Vol 10 No 3    Dunphy et al.
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mice. Nonparametric Kruskal-Wallis and normal theory analy-
sis of variance were performed to determine the
reasonableness of pooling data within control groups (AMV,
neonatal placebo, mature placebo) and within the hormone-
stimulated groups (parous, neonatal E+P, mature E+P). Both
the one-way Kruskal-Wallis nonparametric test of medians and
the one-way analysis of variance test of means were used to
analyze the main effects of Trp53  genotype and hormone
treatment as well as the interactions. The Wilcoxon rank sum
test was used to examine the significance of differences
between means.
Survival curves
The tumor-free survival data were analyzed using survival dis-
tribution with censoring in JMP IN (Duxbury Press, Pacific
Grove, CA, USA). The differences in tumor incidences were
determined by the chi-square test, and differences were con-
sidered statistically significant for P values of less than 0.05.
Results
E+P treatment mimics the effects of parity on responses 
to ionizing radiation
Treatment with E+P for mature (6 to 8 weeks of age) or neo-
natal (10 to 24 days of age) mice resulted in lobular-alveolar
development along the ductal tree and histological features
that were indistinguishable from the glands from parous-invo-
luted mice (Figures 1b and 1e versus 1c and 1f). However, the
architecture of mammary glands from E+P-treated and parous
mice differs from that of glands of 10-week-old nulliparous
mice (Figures 1a and 1d). Therefore, treatment with E+P mim-
ics the effects of parity on mammary gland architecture.
Prior to ionizing radiation, expression of p53 protein was low
in the mammary epithelium. Six hours after ionizing radiation,
weak nuclear accumulation of p53 protein was observed in a
majority of mammary epithelial cells in tissues from placebo-
treated mice (Figures 2C and 2E). In contrast, strong nuclear
p53 staining was observed in mammary tissues from mice that
had received E+P either during the neonatal period or when
mature (Figures 2D and 2F, respectively). Similarly, tissues
from age-matched nulliparous mice had lower levels of p53
staining compared with parous mice (Figures 2G and 2H,
respectively). The staining is specific as Trp53-/- tissues lacked
detectable p53 (Figures 2A and 2B).
For quantification, thresholds were set so that the subset of
cells with strong nuclear accumulation were scored as posi-
tive. The percentage of cells with p53 accumulation was con-
sistently greater in mammary epithelium following hormonal
exposures (Figure 3b). Nuclear accumulation of p53 was more
frequent among mice treated neonatally with E+P compared
with placebo (P < 0.01). Likewise, p53 expression in the mam-
mary epithelium of mature E+P-treated mice and parous mice
was 3- to 4-fold greater than that of mature placebo-treated
mice (P < 0.05). There is no statistical difference in expression
of p53 protein in the mammary epithelium between neonatally
Figure 1
Changes in mammary gland architecture induced by estrogen and progesterone Changes in mammary gland architecture induced by estrogen and progesterone. Tissues from mice that were nulliparous (a, d), E+P-treated (b, e), 
and parous (c, f) were examined using whole mounts (a-c) and 4-μm sections stained with hematoxylin and eosin (d-f). Magnifications, × 4 (a-c) 
and × 100 (d-f). E+P, estrogen and progesterone.Available online http://breast-cancer-research.com/content/10/3/R43
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E+P-treated, mature E+P-treated, or parous mice. Likewise,
there is no statistical difference in expression of p53 protein
between the two placebo groups.
Apoptosis in the mammary epithelium of placebo-treated,
E+P-treated, and parous mice provides a surrogate measure
of p53 activity. As for p53, radiation-induced TUNEL-positive
nuclei were infrequent in the mammary epithelium of placebo-
treated and age-matched virgin mice (Figures 2c, 2e, and 2g)
compared with mice treated with E+P or mice that were
parous (Figures 2d, 2f, and 2h). The lobular and ductal epithe-
lium appear to be similarly sensitized to apoptosis because
TUNEL-positive cells were distributed similarly throughout the
gland. These responses were p53-dependent as radiation-
induced apoptosis was reduced substantially in Trp53-/- mice
(Figures 2a and 2b).
Apoptotic responses to radiation were increased to similar
extents by E+P regardless of whether it was administered neo-
natally or to mature mice and did not differ from radiation-
induced apoptosis detected in parous mice (Figure 3c). The
percentage of apoptosis did not differ between the placebo-
treated mice and AMV mice, so aging is not a factor in acquir-
ing enhanced apoptotic response to radiation (data not
shown). Radiation-induced apoptotic responses in the mam-
mary epithelium from nulliparous Trp53-/- mice were low and
not significantly different from the apoptotic response in the
Trp53+/+ neonatal placebo or mature placebo, suggesting that
p53 response is largely absent in nulliparous mammary tissue
(Figure 3c). However, in Trp53-/- parous mammary epithelium,
apoptotic response to radiation was significantly greater than
in Trp53-/- nulliparous mice, indicating that parity can enhance
apoptosis via p53-independent mechanisms. Though ele-
vated, the responses in Trp53-/- parous glands are 2.5-fold
Figure 2
Radiation-induced accumulation of p53 protein (A-H) and apoptosis (a-h) in mouse mammary glands Radiation-induced accumulation of p53 protein (A-H) and apoptosis (a-h) in mouse mammary glands. Trp53+/+ mice were treated with placebo or 
E+P either neonatally (10 to 24 days old) or when mature (6 to 8 weeks) and then were irradiated to examine nuclear accumulation of p53 and 
TUNEL labeling as indicators of p53 activity. Responses were also examined in mammary tissues from nulliparous mice (AMV = age-matched virgin 
with parous) and following a full-term pregnancy (parous). The absence of staining in Trp53-/- tissues ensures the specificity of p53 immunostaining 
(A, B) and p53 dependence of TUNEL staining (a, b) in placebo- and E+P-treated mice, respectively. Mammary glands from Trp53+/+ mice treated 
with placebo, either neonatally or when mature, exhibited low levels of p53 and TUNEL labeling – (C, E) and (c, e), respectively – and were similar to 
age-matched virgins (G, g). In contrast, both p53+ nuclei and TUNEL labeling were prevalent in the mammary tissues from Trp53+/+ mice treated 
with E+P either neonatally or at maturity – (D, d) and (F, f), respectively – and were similar to glands from parous mice (H, h). All images were taken 
at × 400. E+P, estradiol and progesterone; IHC, immunohistochemistry; Trp53, transformation-related protein 53 (gene in mouse encoding the p53 
tumor suppressor protein); TUNEL, terminal uridine deoxynucleotidyl transferase dUTP nick-end labeling.Breast Cancer Research    Vol 10 No 3    Dunphy et al.
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Figure 3
Responses to irradiation in the mammary epithelium are enhanced by hormonal treatments Responses to irradiation in the mammary epithelium are enhanced by hormonal treatments. (a) The timeline summarizes treatment schedules of 
mice. Pellets obtained from Innovative Research of America (Sarasota, FL, USA) were used to deliver either E+P to mice for 14 days (neonatal E+P 
or mature E+P). Placebo groups were implanted with control pellets at these times. Mice were mated starting at 5 weeks of age and nursed pups for 
1 week, and then mammary glands were allowed to involute for 4 weeks post-weaning to produce parous females. Tissues were harvested to deter-
mine basal levels of p53 and TUNEL labeling or irradiated 6 hours prior to harvest to determine responses following DNA damage. (b) Radiation-
induced accumulation of p53 was increased significantly by neonatal E+P and mature E+P compared with the placebo-treated controls. The propor-
tion of p53+ mammary epithelial cells in the E+P-treated groups did not differ from that in parous mice. The tissues from Trp53-/- mice were devoid of 
immunoreactive p53. (c) Radiation-induced TUNEL labeling also showed significant increases following treatment with neonatal E+P and mature 
E+P compared with the placebo-treated controls. Radiation-induced apoptosis was diminished in Trp53-/- tissues compared with Trp53+/+. How-
ever, the proportion of TUNEL-positive epithelial cells in parous Trp53-/- was increased compared with the placebo-treated Trp53-/- controls. (d) Lev-
els of spontaneous apoptosis were low in nulliparous mice but increased significantly by neonatal E+P and were similar to the levels observed in 
tissues from parous mice. No significant difference in TUNEL labeling was detected in Trp53-/- tissues from nulliparous and neonatal E+P-treated 
mice. Bars indicate statistical differences between means: *P < 0.05; **P < 0.01. E+P, estradiol and progesterone; Trp53, transformation-related 
protein 53 (gene in mouse encoding the p53 tumor suppressor protein); TUNEL, terminal uridine deoxynucleotidyl transferase dUTP nick-end 
labeling.Available online http://breast-cancer-research.com/content/10/3/R43
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lower than Trp53+/+  parous glands (4.0% versus 11.0%,
respectively;  P  < 0.05), indicating that a majority of the
response in tissues from Trp53+/+ mice is p53-dependent.
Spontaneous apoptosis was also compared for the Trp53+/+
and Trp53-/- genotypes. Basal levels of apoptosis in Trp53+/+
tissues were significantly increased in E+P-treated and parous
mice compared with nulliparous mice (Figure 3d). Basal levels
of apoptosis were also detected in Trp53-/- tissues, but there
was no statistical difference between nulliparous and E+P-
treated mice.
Both the results for radiation-induced p53 accumulation and
TUNEL-positive epithelial cells demonstrate that exposure to
E+P results in an increase in p53 responsiveness to radiation
that is similar to the effect of parity and that is sustained for at
least 7 weeks beyond hormone exposure and that E+P treat-
ment is effective regardless of the age at which mice are
treated. The majority of the apoptosis in hormone-stimulated
tissues depends on p53, but some p53-independent radia-
tion-induced apoptosis was also detected.
Enhanced apoptotic responses are retained following 
withdrawal of estrogen and progesterone
To test whether endogenous E+P is necessary to maintain the
elevated apoptotic responses to radiation in E+P-treated
epithelium, nulliparous females were treated with E+P or pla-
cebo pellets at 6 to 8 weeks of age (Figure 4a). The mammary
tissues were allowed to regress for 2 weeks following the hor-
mone treatments and then the mice were ovariectomized. The
mice were allowed to recover for 2 weeks following ovariec-
tomy to clear endogenous hormones. Radiation-induced
apoptosis was retained in the E+P-treated mice even after
ovariectomy (Figures 4b and 4c). The radiation responses did
not differ from ovary-intact animals. These results imply that
E+P treatment induces chronic changes in p53-dependent
apoptotic responses to ionizing radiation and continued expo-
sure to ovarian hormones is not necessary.
To determine whether effects of hormone stimulation were
intrinsic to the mammary gland, whole mammary glands from
placebo- and E+P-treated mice were cultured in control media
or media supplemented with E+P (Figure 5a). Radiation-
induced apoptosis in the nulliparous mammary epithelium was
low in control media and increased modestly in E+P media
(Figures 5b and 5c, i and iii). In contrast, mammary glands from
mice that had been treated with E+P in vivo had statistically
greater apoptotic response to irradiation in both control and
E+P media (Figures 5b and 5c, ii and iv). Thus, increased
responsiveness to radiation is intrinsic to hormone-treated
mammary tissues and is retained even after removal from sys-
temic influences by placing tissues in whole organ culture.
Taken together, these data demonstrate that E+P-treated
mammary glands are primed to be more responsive to irradia-
tion than the nulliparous glands and that this response is inde-
pendent of the continued presence of ovarian hormones
(Figure 4b) or systemic factors (Figure 5b). The high apoptotic
response of the E+P-treated glands occurs equally in main
Figure 4
Increases in radiation-induced apoptosis are retained in E+P-treated mice after ovariectomy Increases in radiation-induced apoptosis are retained in E+P-treated mice after ovariectomy. (a) Mice were treated with E+P or placebo at 6 to 8 
weeks of age. At 10 weeks of age, mice were ovariectomized and endogenous hormones were allowed to clear for 2 weeks. All mice received a 5-
Gy dose of radiation 6 hours prior to tissue harvest. (b) Radiation-induced apoptosis was increased in mammary tissues from E+P-treated mice 
compared with the placebo-treated controls (*P < 0.01). (c) TUNEL-positive epithelial cells were minimal in ducts from nulliparous ovariectomized 
mice (i) but were detected frequently in tissues from mice that were E+P-treated and ovariectomized (ii). All images were taken at × 400. E+P, 
estradiol and progesterone; IR, ionizing radiation; OVX, ovariectomized; TUNEL, terminal uridine deoxynucleotidyl transferase dUTP nick-end 
labeling.Breast Cancer Research    Vol 10 No 3    Dunphy et al.
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branching ducts (Figure 5c, iv) as it does in the lobulo-alveolar
structures. Thus, the apoptotic response to irradiation in all of
these experiments is not specific to a particular structure
within the mature mammary gland.
Parity is protective in the BALB/c-Trp53+/- mice
BALB/c-Trp53+/-  mice develop spontaneous mammary
tumors, providing a model for breast cancer in Li-Fraumeni
syndrome [32]. Therefore, we compared the effects of Trp53
genotype and hormonal treatments on radiation-induced
apoptosis in mammary tissues. As no differences in responses
were detected within the nulliparous control groups (AMV,
neonatal placebo, mature placebo) or within the hormone-
stimulated groups (parous, neonatal E+P, mature E+P), the
data for these groups were pooled (as described in Materials
and methods). This was necessary due to the spontaneous
nonmammary tumors that are common among the Trp53-defi-
cient mice and limited survival. The overall effect of Trp53 gen-
otype was significant in both the nulliparous control and
hormone-stimulated groups (Kruskal-Wallis test, P = 0.04 and
Figure 5
Radiation-induced apoptosis in the mammary epithelium is not dependent on systemic factors Radiation-induced apoptosis in the mammary epithelium is not dependent on systemic factors. (a) Timeline for whole organ culture (WOC) experi-
ments. Mice were treated with placebo or E+P at 6 to 8 weeks of age. At tissue harvest, contralateral fourth mammary glands were placed in either 
serum-free control media or media supplemented with E+P. Mammary glands were maintained in WOC for 3 days followed by a 5-Gy dose of irradi-
ation 6 hours prior to harvesting and fixing the tissue. (b) Mammary glands from mice treated with E+P in vivo had a significantly greater apoptotic 
response to radiation compared with the placebo-treated controls. The increase due to E+P in vivo was evident regardless of whether the tissues 
were maintained in serum-free control media or media supplemented with E+P (*P < 0.01). (c) TUNEL-positive staining is shown for placebo-treated 
glands in control media (i), E+P-treated glands in control media (ii), placebo-treated glands in E+P-treated media (iii), and E+P-treated glands in 
E+P media (iv). Panels (i-iii) were taken at × 400. Panel (iv) was taken at × 200 to show that TUNEL-positive cells were present throughout all 
structures of the E+P-treated glands. E+P, estradiol and progesterone; IR, ionizing radiation; TUNEL, terminal uridine deoxynucleotidyl transferase 
dUTP nick-end labeling.Available online http://breast-cancer-research.com/content/10/3/R43
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0.002, respectively). In the nulliparous group, responses in the
Trp53+/+ mice were significantly greater than either Trp53+/- or
Trp53-/-  (Figure 6a). Apoptotic responses were also
decreased significantly with decreasing dosage of Trp53 in
the hormone-stimulated mice (P < 0.05). Thus, Trp53+/- mam-
mary tissue is haploinsufficient with respect to radiation-
induced apoptosis, but p53 activity can be increased signifi-
cantly in Trp53+/-  mammary epithelium following hormonal
stimulation.
To test whether the increased activity of p53 following hormo-
nal stimulation alters tumorigenesis, we compared incidence
and latency of spontaneous mammary tumors between nullipa-
rous  Trp53+/-  mice and parous Trp53+/-  mice. Mammary
tumors occurred in 43.2% of the nulliparous mice and 34.6%
of the parous mice. Mammary tumor-free survival time was
increased by 15 weeks in the parous group (Figure 6b) (P <
0.0001). Therefore, parity is effective in protecting from mam-
mary tumors in this mouse model of Li-Fraumeni syndrome.
Figure 6
Effects of hormonal treatments on apoptosis in BALB/c-Trp53+/- mammary glands Effects of hormonal treatments on apoptosis in BALB/c-Trp53+/- mammary glands. (a) Levels of TUNEL-positive mammary epithelium from nullipa-
rous mice were decreased significantly with dosage of Trp53 (Trp53+/+ > Trp53+/- > Trp53-/-) in both nulliparous and hormone-stimulated groups. 
Data from control groups and hormone-treated groups of mice were pooled to provide sufficient numbers for all genotypes. The nulliparous group 
represents placebo-treated and age-matched virgins. The hormone-stimulated group represents mammary tissues from mice treated with E+P and 
parous mice as described in Figure 2a. Bars indicate statistical differences between means: *P < 0.05; **P < 0.01.(b) The incidence of mammary 
tumors was monitored in both nulliparous and multiparous BALB/c-Trp53+/- female mice. The latency of spontaneous mammary tumors was 
increased in parous compared with nulliparous mice (P < 0.001). TUNEL, terminal uridine deoxynucleotidyl transferase dUTP nick-end labeling.Breast Cancer Research    Vol 10 No 3    Dunphy et al.
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The histopathology and ERα status of the tumors were also
examined to determine whether parity altered the subtypes of
tumors in the BALB/c-Trp53+/- mice. Adenocarcinomas repre-
sented the dominant histopathological class of tumors in both
nulliparous and parous mice (Table 1) (86.2% and 87.5%,
respectively). Although mammary intra-epithelial neoplasias
(MINs) are considered precursors of adenocarcinomas, these
were a small proportion of tissues because only palpable
lesions were collected. Carcinosarcomas and adenosqua-
mous tumors were infrequent. Expression of ERα was
detected in MIN and adenocarcinomas (Figure 7). Among
adenocarcinomas, the proportion positive for ERα was
increased from 12% among the nulliparous group to 33%
among the parous group (Table 1) (P < 0.001). The increase
in ERα+ tumors may reflect a difference in the cellular origins
of the tumors between nulliparous and parous mice. However,
this may be confounded with the fact that the mammary tumors
in older mice are often collected at an earlier stage of tumor
progression because of comorbidities (for example, lympho-
mas). The mammary tumors in BALB/c-Trp53+/- mice appear
to progress from ERα+ lesions to ERα- tumors (D.J. Jerry,
unpublished data). Thus, the difference in ERα expression may
reflect an earlier stage of progression among mammary tumors
from parous mice due to the longer latencies.
The protective effect of parity and E+P treatment is not 
retained in epithelial transplants
Parity offers lifetime resistance to mammary tumorigenesis
despite the fact that the parous epithelium will go through
repeated cycles of proliferation and regression at each estrus
cycle and with each pregnancy. Therefore, the protective
effect may be programmed into mammary epithelial cells, and
specifically mammary epithelial progenitor cells. If this is the
case, mammary epithelium from a hormone-stimulated donor
transplanted into the cleared fat pad of a nulliparous host
should retain protective features. Therefore, we tested
whether the apoptotic response to radiation was retained by
the epithelial outgrowths that originate from E+P-treated or
parous tissue (Figure 8a). There was no difference in radiation-
induced apoptosis between Trp53+/-  epithelial outgrowths
from nulliparous, E+P-treated, or parous donors. Apoptosis in
Trp53+/- epithelial outgrowths (Figure 8b) did not differ from
the Trp53+/- nulliparous epithelium from glands of ovary-intact
mice (Figure 6a). Although E+P treatment enhanced radiation-
induced apoptosis in donor tissues (Figure 6a), apoptotic
responses to radiation were significantly lower among out-
growths of Trp53+/- mammary epithelium regardless of the
treatment of the donor tissue (Figure 8b). Thus, the out-
growths failed to retain the sensitivity to radiation that was
present in the donor tissue.
To determine whether transplanted epithelium from E+P-
treated donors may retain the protective effects of the hor-
mone stimulation after transplantation into the cleared fat pad
of nulliparous hosts, we compared tumor incidence and
latency between glands bearing transplants of Trp53+/- mam-
mary epithelium from nulliparous versus E+P-treated donor
mice. All tumors from the transplanted epithelium, whether
E+P-treated or nulliparous, developed adenocarcinomas with
similar histopathological features. There was no significant dif-
ference in tumor incidence or latency between the epithelium
from the E+P-treated donor or the nulliparous donor (Figure
9). Because mammary tumorigenesis is not reduced in the
E+P-treated epithelium compared with the nulliparous epithe-
lium and because the radiation-induced apoptotic response is
not retained by the hormone-stimulated outgrowths, the parity-
induced changes are not a stable phenotype retained by the
epithelial progenitor cells that repopulate the gland.
Discussion
The significant role of p53 in tumor suppression in the mam-
mary epithelium was demonstrated by the frequent occur-
rence of spontaneous tumors in transplants of BALB/c-Trp53-
/- mammary epithelium [22]. As p53 protein promotes cell
cycle arrest and apoptosis, both can play significant roles in
tumor suppression. However, only the proapoptotic function is
Table 1
Characteristics of spontaneous mammary tumors in BALB/c-Trp53+/- mice
Reproductive history Histopathology Number Frequency ERα-positive
Nulliparous Mammary intra-epithelial neoplasia 1 3.4% 1
Adenocarcinoma 25 86.2% 3
Carcinosarcoma 1 3.4% 0
Adenosquamous 2 6.8% 0
Parous Mammary intra-epithelial neoplasia 2 8.3% 0
Adenocarcinoma 21 87.5% 7
Carcinosarcoma 0 0 0
Adenosquamous 1 4.2% 0
ERα, estrogen receptor-alpha.Available online http://breast-cancer-research.com/content/10/3/R43
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required to prevent lymphomas whereas the cell cycle
checkpoint activity is dispensable [33]. Therefore, enhance-
ment of apoptosis in the mammary epithelium appears to be a
critical activity for suppression of tumors. Both radiation-
induced and spontaneous apoptosis were enhanced in parous
and E+P-treated mammary epithelium (Figures 3c and 3d). As
radiation-induced apoptosis was 2.5-fold higher in Trp53+/+
mammary tissues than the Trp53-/- after hormonal stimulation
(Figure 6a), the majority of apoptosis is p53-dependent.
Though lower in magnitude, apoptosis in the mammary epithe-
lium of Trp53-/- mice was also increased by E+P treatment
(Figure 6a). Therefore, in addition to enhancing p53 function,
hormonal exposures appear to alter the promotional environ-
ment of the host to enhance p53-independent apoptosis path-
ways [34], both of which may contribute to tumor suppression.
Inducible expression of p53 in mouse models has shown that
even short-term expression of p53 can substantially delay the
appearance of lymphomas and liver carcinomas [35,36].
Therefore, the duration of the enhancement of p53 was of
interest. Treatment with E+P for 14 days stimulated changes
in the mammary epithelium such that p53-dependent apopto-
sis in the mammary epithelium persisted even after ovariec-
tomy, indicating that continued exposure to ovarian hormones
is not necessary to maintain p53 activity. These results imply
that neither the nulliparous nor parous glands are necessarily
more vulnerable to genotoxic stress at one phase of the estrus
cycle or another. Rather, there is an enhancement of apoptosis
that is sustained long after pregnancy and even after cessation
of ovarian function.
Breast cancer is the most common tumor among females with
Li-Fraumeni syndrome, which is most often associated with
heterozygous mutations in the gene encoding p53 [28],
underscoring the prominent role of TP53 in determining breast
cancer susceptibility. However, it is not clear whether the risk
Figure 7
Estrogen receptor-alpha expression in spontaneous mammary tumors in Trp53+/- mice Estrogen receptor-alpha expression in spontaneous mammary tumors in Trp53+/- mice. Spontaneous mammary tumors from nulliparous (i-iii) and 
parous (iv-vi) BALB/c-Trp53+/- mice were stained with anti-ERα antibodies. Representative sections are shown for mammary intra-epithelial neopla-
sias (MIN) and adenocarcinomas that differ in ERα status. The tissues from nulliparous mice include (i) ERα+ MIN, (ii) ERα- adenocarcinoma, and 
(iii) ERα+ adenocarcinoma. The tissues from parous mice include (iv) ERα- MIN, (v) ERα- adenocarcinoma, and (vi) ERα+ adenocarcinoma. Scale 
bar = 20 μm. ERα, estrogen receptor-alpha.Breast Cancer Research    Vol 10 No 3    Dunphy et al.
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of breast cancer among women with Li-Fraumeni syndrome is
due to reduced activity of p53 or the increased risk of losing
the wild-type allele of TP53. As levels of radiation-induced
apoptosis in Trp53+/- mouse mammary epithelium were inter-
mediate to the responses in Trp53+/+ and Trp53-/- tissues (Fig-
ure 6a), Trp53+/- mammary tissues are haploinsufficient with
respect to apoptosis. This intermediate apoptotic response
phenotype is consistent with apoptosis observed in Trp53+/-
mice during involution of the prostate following castration [37].
Stress responses were also attenuated in HCT116 cells that
were heterozygous for TP53 compared with the wild-type cells
[38]. Thus, the activity of p53 may fall below a threshold in
Trp53+/- mammary epithelium, as proposed by Santarosa and
Ashworth [39], to a point that is no longer sufficient to engage
appropriate apoptotic responses to genotoxic stress. The
appearance of spontaneous mammary tumors was delayed
among parous BALB/c-Trp53+/- mice (Figure 6b). Therefore,
the activity of p53 is reduced to critical levels in the mammary
epithelium of BALB/c-Trp53+/- mice, but hormonal stimulation
increases p53-dependent apoptosis and renders the tissue
more resistant to tumorigenesis. As parity did not prevent
tumors in BALB/c-Trp53-/-  mammary epithelial transplants
[22], the decrease in mammary tumors among parous BALB/
c-Trp53+/- (Figure 6b) appears to be largely p53-dependent.
The mechanism by which E+P sensitizes the p53 pathway is
initiated by their respective receptors [27]. In women, the pro-
tective effects of parity are limited to the ERα+/progesterone
receptor-positive tumors [40]. Thus, we investigated whether
parity diminished the proportion of ERα+ tumors in BALB/c-
Figure 8
The protective effects of E+P treatment are not retained in epithelial transplant outgrowths The protective effects of E+P treatment are not retained in epithelial transplant outgrowths. (a) Donor tissues were obtained from Trp53+/- mice that 
were treated as summarized in the diagram. One group of mice was implanted with pellets containing either no hormones or E+P. Another group of 
mice was allowed to undergo a full-term pregnancy or remained unmated to provide age-matched nulliparous tissue. (b) Radiation-induced apopto-
sis was determined in outgrowths of Trp53+/- mammary tissue transplanted into wild-type hosts. The timeline of treatments is summarized graphically 
in the upper panel. The Trp53+/- mammary tissues from donors, described in panel (a), were transplanted into mammary fat pads of 3-week-old wild-
type hosts and allowed to fill the glands. When 10 weeks old, the transplant-bearing hosts were irradiated 6 hours prior to tissue harvest. Radiation-
induced apoptosis was low and did not differ among the mammary epithelial outgrowths from Trp53+/- placebo-treated, E+P-treated, age-matched 
virgin (AMV), or parous mammary tissues. E+P, estradiol and progesterone; Trp53, transformation-related protein 53 (gene in mouse encoding the 
p53 tumor suppressor protein); TUNEL, terminal uridine deoxynucleotidyl transferase dUTP nick-end labeling.Available online http://breast-cancer-research.com/content/10/3/R43
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Trp53+/- mice. In contrast to expectations, the proportion of
ERα+ tumors was increased among parous mice (Table 1).
ERα+ mammary tumors were also observed in C57BL/6J mice
rendered p53-deficient by inducible deletion by WAP/Cre
[41]. However, these results should be interpreted with cau-
tion because ERα status is confounded with age of mice.
Since mammary tumors in BALB/c-Trp53+/- mice progress
from ERα+ lesions to ERα- tumors (K.A. Dunphy, A.C. Black-
burn, H. Yan, L.R. O'Connell, D.J. Jerry, unpublished data), the
ERα expression observed among mammary tumors in parous
mice may reflect an earlier stage of progression due to the
longer latencies. Additional markers to distinguish basal-like
and luminal properties will be needed in order to ascertain
whether the cellular origins differ for the mammary tumors in
nulliparous and parous BALB/c-Trp53+/- mice.
Decreased expression of ERα and increased expression of
ERβ are persistent changes observed in mammary epithelium
of parous rodents [8]. ERα and ERβ exert antagonistic effects
on p53 activity [42,43]. This could explain the increased p53-
dependent apopotosis in hormone-stimulated mammary tis-
sues. Alternatively, the persistent phenotypic changes in ERs
and responsiveness of p53 may reflect alterations in the fates
of the progenitor cell pool. Indeed, parity-induced mammary
epithelial cells have been identified and serve as progenitors
of the lobulo-alveolar structures during subsequent pregnan-
cies [44,45]. However, outgrowths of Trp53+/- mammary epi-
thelium from E+P-treated and parous mice failed to retain the
elevated apoptotic response to radiation in nulliparous hosts
(Figure 9). The characteristics of the outgrowths were not dif-
ferent from nulliparous transplants or nulliparous glands
(Figure 6a). Likewise, the outgrowths of E+P-treated Trp53+/-
mammary epithelium developed tumors with frequency and
latency similar to those of the Trp53+/- transplants from nullipa-
rous mice (Figure 9).
These observations do not preclude the possibility that the
fates or number of stem cells may be decreased within the
mammary glands of hormone-stimulated mice compared with
nulliparous mice. It remains possible that parity decreases the
pool of progenitor cells [46] but does not limit the capacity of
the stem cells to repopulate upon transplantation. It is equally
possible that hormonal stimulation imparts a stable change in
the stromal cells and extracellular matrix which modulate p53
function. The extracellular matrix from involuting glands can
promote tumors [17,18] but also is essential for differentiation
Figure 9
Tumor-free survival in BALB/c mice bearing transplants of Trp53+/- mammary epithelium Tumor-free survival in BALB/c mice bearing transplants of Trp53+/- mammary epithelium. Tumor incidence was also determined for outgrowths of 
Trp53+/- mammary tissue transplanted into wild-type hosts. The timeline of treatments is summarized graphically in the upper panel. Donor mammary 
tissues from Trp53+/- mice (described in Figure 8a) were transplanted into epithelium-free mammary fat pads of 3-week-old wild-type mice. Begin-
ning at 10 weeks of age, host mice received a 1.2-Gy dose of ionizing radiation once a week for 4 weeks to induce mammary tumors as described 
previously [30]. Mice were palpated weekly for mammary tumors until 65 weeks old. The incidence and latency of mammary tumors did not differ 
between epithelial outgrowths from the Trp53+/- mammary tissues from E+P-treated donors and nulliparous donors (P > 0.05). E+P, estradiol and 
progesterone; IR, ionizing radiation; Trp53, transformation-related protein 53 (gene in mouse encoding the p53 tumor suppressor protein); TUNEL, 
terminal uridine deoxynucleotidyl transferase dUTP nick-end labeling.Breast Cancer Research    Vol 10 No 3    Dunphy et al.
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[47,48], and parous stroma decreased the incidence of
tumors [49]. Many extracellular matrix proteins change dramat-
ically across developmental phases and can alter integrin-
mediated signaling in the mammary gland [19,50,51]. Loss of
integrin signaling results in apoptosis in the mammary epithe-
lium [52]. Therefore, hormonal stimulation may result in stable
changes within the stroma which limit either tumorigenic trans-
formation of progenitor cells or their progression to invasive
tumors.
Conclusion
These results demonstrate that E+P and parity enhance p53-
dependent responses to radiation to a similar extent.
Increased p53 surveillance and clearance of compromised
cells by apoptosis is likely a critical activity that reduces tumors
in parous individuals. The heightened sensitivity of p53 is sus-
tained even after withdrawal of ovarian hormones. While the
parity-influenced apoptotic mechanism is intrinsic to the mam-
mary gland itself, it is not permanently programmed into the
epithelial progenitor cells. Thus, the heightened surveillance of
parous mammary epithelium was lost when transplanted into
cleared mammary fat pads of nulliparous mice and the trans-
planted epithelium acquired the tumor incidence of the host.
This suggests a mechanism in which the hormones act on the
stroma as well as the epithelium to communicate reciprocally
to enhance p53-dependent apoptosis.
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